Tags
- A
- Acro
- Across
- Advancement
- Adverse
- Adverse event
- Adverse Events
- Aggressive
- Alone
- An
- Benefit
- Benefits
- Cancer
- Carcinoma
- Care
- China
- Clinic
- Clinical
- Clinical endpoint
- Clinical governance
- Clinical trial
- Clinician
- Combination
- Combination therapy
- Combined
- Combining
- Compulsion
- Conducting
- Content
- Death
- Demonstrate
- Disease
- Endpoint
- Enhance
- E.T.
- Evaluation
- Evidence
- Fan
- Five
- Follow-up
- Follow-up period
- HCC
- Hepatectomy
- Hepatocellular
- Hepatocellular carcinoma
- Hospital
- Improved
- Inhibitor
- Integration
- In Treatment
- Invasion
- Liver
- Liver cancer
- Marks
- Metric
- Metrics
- Multicenter trial
- Multikinase inhibitor
- MVI
- New
- New Standard
- No
- Open-label trial
- Over
- Participation
- Patient
- Patient outcome
- Pharmacovigilance
- Phase
- Phase III
- Population
- Positive
- Primary
- Profile
- Prognosis
- Progression-free survival
- Promising
- Quality
- Quality of life
- Ran
- Randomization
- Randomized controlled trial
- Randomness
- Recurrence
- Response rate
- Result
- Retrospective
- Retrospective cohort study
- Safety
- Secondary
- Shown
- Sorafenib
- Standard of care
- Step Forward
- Strategy
- Strike
- Studie
- Superior
- Survival
- Survival rate
- TACE
- The Combined
- The Objective
- Therapy
- The trial
- Trial
- Underscore
- Unexpected
- Versus
- W
- Widespread